Shanghai Medicilon
- Company typePrivate
- Founded2004
- HeadquartersShanghai, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
Shanghai Medicilon firmographics
Firmographics- Name
- Shanghai Medicilon
- Legal name
- Medicilon
- Website
- https://medicilon.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Shanghai Medicilon industry classification
Industry- Product category
- Preclinical Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Shanghai Medicilon is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
Shanghai Medicilon business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Fee-for-Service (FFS) and FTE Models: Medicilon provides preclinical CRO services using fee-for-service (FFS) and full-time equivalent (FTE) models. The FFS model is used for specific compound synthesis and studies, while FTE models provide dedicated chemist resources for ongoing projects. Services span drug discovery, CMC development, and preclinical research with pricing based on study type, duration, and resource allocation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Shanghai Medicilon product offering
Product offeringCore offering
Shanghai Medicilon is a preclinical contract research organization (CRO) that provides integrated drug discovery, CMC (chemistry, manufacturing and controls) development, and IND-enabling preclinical research services to pharmaceutical and biotechnology companies. Its offering spans discovery chemistry and biology, process development and formulation, and safety assessment / regulatory support, backed by advanced technology platforms for peptides, siRNA, ADCs, PROTACs, AOCs, and NAMs toxicology.
Product overview
Medicilon is an integrated preclinical CRO offering unified drug development services spanning drug discovery (chemistry and biology), CMC development, and preclinical research. The portfolio includes core service lines (Drug Discovery Services, CMC Development, Preclinical Research Services) supplemented by six advanced technology platforms: Peptide Drug Discovery Platform (mRNA display), siRNA Platform, ADC Platform, PROTAC Platform, AOC Biology Platform, and NAMs Platform. The company operates from Shanghai with facilities in the US (Boston Innovation Center), supporting 580+ IND-approved projects with over 20 years of experience serving global pharmaceutical and biotech clients.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Discovery Services
Quantifiable outcome
- 580+ IND-approved projects delivered
- +5 more outcomes
Companies that use Shanghai Medicilon
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles1 record
Shanghai Medicilon technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Shanghai Medicilon partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Oncotelic TherapeuticscoreMedicilon supports Oncotelic Therapeutics' Sapu003 (Deciparticle formulation of everolimus) Phase 1b trial for advanced mTOR-sensitive solid tumors. The joint venture GMP Biotechnology Limited is advancing multiple Deciparticle nanoparticle candidates including OT-101/IL-2 combination therapy. Medicilon's CMC and preclinical capabilities support the JV pipeline including formalization of GMP Bio subsidiaries (Sapu Bio and Sapu Nano).
- Otsuka PharmaceuticalminorOtsuka Pharmaceutical acquired US-based Jnana Therapeutics Inc. in August 2024, gaining access to the oral therapy candidate JNT-517 for phenylketonuria and additional autoimmune pipeline programs. This represents an acquisition rather than a partnership with Medicilon.
- Calibr (Scripps Research)minorAbbVie extended its partnership with Calibr (a division of Scripps Research) in July 2023 to jointly advance preclinical and early clinical assets, building on an existing relationship. This represents a third-party partnership referenced in market news rather than a direct Medicilon partnership.
Scale indicators15 records
Recent moves6 records
Expansion highlights5 records
Shanghai Medicilon competitors and assessment
Company assessmentDirect peers
- WuXi AppTec: China-based, full-service preclinical and clinical CRO/CDMO with global footprint. Directly comparable integrated discovery-to-IND platform, though materially larger and broader in scope than Medicilon.
- Pharmaron: China-headquartered preclinical CRO/CDMO offering drug discovery, CMC, DMPK, and safety assessment. Closest head-to-head competitor to Medicilon in the integrated preclinical CRO space.
- Charles River Laboratories: Global leader in preclinical CRO services including safety assessment, DMPK, and research models. Directly comparable on the preclinical and safety-assessment side of Medicilon's portfolio.
- Labcorp Drug Development (Covance): Major global CRO offering preclinical through clinical services with strong DMPK, safety, and CMC capabilities. Comparable end-to-end preclinical offering for large pharma and biotech clients.
- Asymchem Laboratories: China-based API CDMO with preclinical chemistry and CMC capabilities. Comparable on the small-molecule CMC and process development side of Medicilon's service portfolio.
- Frontage Laboratories: US- and China-based CRO offering preclinical DMPK, safety, CMC, and bioanalytical services. Comparable integrated preclinical offering with similar US-China dual presence.
Regional players
- Tigermed: China-headquartered clinical CRO with growing preclinical/biomarker capabilities. More clinical-stage focused than Medicilon but competes for the same Chinese biotech R&D budgets.
Broad incumbents
- WuXi Biologics: Global biologics CDMO/CRO offering antibody discovery, cell line development, and biologics manufacturing. Overlaps with Medicilon's antibody/ADC discovery capabilities.
- Eurofins Discovery: Global CRO providing drug discovery, pharmacology, and safety services across multiple modalities. Broader scope but competes for outsourced discovery and preclinical budgets.
- IQVIA: World's largest CRO with preclinical through clinical capabilities. While primarily clinical-stage, IQVIA's preclinical services compete with Medicilon for large enterprise pharma contracts.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Shanghai Medicilon social profiles
Digital presenceShanghai Medicilon compliance and trust
Trust signalCompliance9 records
Shanghai Medicilon financial estimates
Financial estimateRevenue estimate
Valuation estimate
Shanghai Medicilon leadership team
Management profileNumber of profiles
Profiles2 records
Shanghai Medicilon funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Shanghai Medicilon M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Shanghai Medicilon
What does Shanghai Medicilon do?
Shanghai Medicilon is a preclinical contract research organization (CRO) that provides integrated drug discovery, CMC (chemistry, manufacturing and controls) development, and IND-enabling preclinical research services to pharmaceutical and biotechnology companies. Its offering spans discovery chemistry and biology, process development and formulation, and safety assessment / regulatory support, backed by advanced technology platforms for peptides, siRNA, ADCs, PROTACs, AOCs, and NAMs toxicology.
Is Shanghai Medicilon a public or private company?
Shanghai Medicilon is a private company. It is classified as public and is currently operating.
When was Shanghai Medicilon founded?
Shanghai Medicilon was founded in 2004. It employs 1,001 to 5,000 people.
Where is Shanghai Medicilon based?
Shanghai Medicilon is headquartered in Shanghai, China, in the Asia region.
How does Shanghai Medicilon make money?
One revenue line is on record: fee-for-Service (FFS) and FTE Models.
Who are Shanghai Medicilon's main competitors?
Direct peers on record are WuXi AppTec, Pharmaron, Charles River Laboratories, Labcorp Drug Development (Covance), Asymchem Laboratories and Frontage Laboratories. Tigermed is listed as a regional player. Broad incumbents are WuXi Biologics, Eurofins Discovery and IQVIA.
Does Shanghai Medicilon have an API?
No public API is recorded for Shanghai Medicilon.
What industry is Shanghai Medicilon in?
Shanghai Medicilon's product category is Preclinical Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 5417 and its SIC code is 8731.